The U.S. stock market showcased a mixed but overall positive performance today, as major indexes are set to record their strongest month since October 2022 for the Dow and S&P, and since...
Goldman Sachs analysts initiate coverage on Iovanace Biotherapeutics (IOVA) with a Buy rating and a price target of $12.00.The analysts comment "We initiate on Iovance Biotherapeutics...
An analyst from Stifel maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'buy' with a price target of $22.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from H.C. Wainwright maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'buy' with a price target of $28.00 from a prior price target of %currency%%price%. Prior to this...
Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA) reported third quarter EPS of $-0.46, $0.01 worse than the analyst estimate of $-0.45. Revenue for the quarter came in at $469K versus...
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel...
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel...
An analyst from Barclays maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'overweight' with a price target of $18.00 from a prior price target of %currency%%price%. Prior to this...
Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients...
An analyst from Stifel maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'buy' with a price target of $25.00 from a prior price target of %currency%%price%. Prior to this rating,...
An analyst from Baird maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'outperform' with a price target of $20.00 from a prior price target of %currency%%price%. Prior to this rating,...
Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA) reported second quarter EPS of $-0.47, $0.03 better than the analyst estimate of $-0.50. Revenue for the quarter came in at $240K...
Investing.com -- Shares in Iovance Biotherapeutics Inc (NASDAQ:IOVA) dropped sharply in premarket U.S. trading on Tuesday after the biotechnology firm announced the pricing of an...
Iovance Biotherapeutics, Inc. (Nasdaq: NASDAQ:IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...
VOXX International Corporation (NASDAQ:VOXX) 16% LOWER; {{erl-17502||reported Q1 EPS of ($0.45), $0.41 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $111.93...
Iovance Biotherapeutics, Inc. (Nasdaq: NASDAQ:IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...
An analyst from Stifel maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'buy' with a price target of $27.00 from a prior price target of %currency%%price%. Prior to this rating,...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for...
Iovance Biotherapeutics (NASDAQ:IOVA) has filed mixed shelf of:Common StockPreferred StockDebt SecuritiesWarrantsUnitsRights to Purchase Common Stock, Preferred Stock, Debt Securities or...
Investing.com -- Stocks are mixed on Tuesday on hopes about a tentative agreement on the debt ceiling despite objections from some lawmakers. Here are the market movers for May 30. NVIDIA...
An analyst from Wells Fargo upgraded Iovance Biotherapeutics (NASDAQ: IOVA) from 'equal weight' to 'overweight' with a price target of $17.00 from a prior price target of...
An analyst from Stifel maintained Iovance Biotherapeutics (NASDAQ: IOVA) at 'buy' with a price target of $24.00 from a prior price target of %currency%%price%. Prior to this rating,...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for...
An analyst from Baird maintained Iovance Biotherapeutics (NASDAQ: IOVA) at '' 'outperform' and a price target of $20.00 from a prior price target of %currency%%price%. Prior to this rating,...
Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA) reported first quarter EPS of $-0.50, $0.07 better than the analyst estimate of $-0.57. Revenue for the quarter came in at $0.00 versus...
A Wells Fargo analyst initiated new coverage Iovance Biotherapeutics (NASDAQ: IOVA) Equal Weight rating and a price target of $11.00. Prior to this rating, Iovance Biotherapeutics had 9...
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its rolling Biologics...
Investing.com - Iovance Biotherapeutics (NASDAQ: IOVA) reported fourth quarter EPS of $-0.64, in line with the analyst estimate of $-0.64. Revenue for the quarter came in at $0.00 versus the...
Iovance Biotherapeutics (NASDAQ:IOVA) reported Q4 EPS of ($0.64), in-line with the analyst estimate of ($0.64).
By Sam Boughedda Iovance Biotherapeutics (NASDAQ:IOVA) was raised to Overweight from Neutral by Piper Sandler analysts on Friday, who stated that it finally feels like the story is "maybe...
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Technology, Consumer Services and Industrials sectors propelled shares higher. At the close in NYSE, the...
By Sam Boughedda Investing.com -- US equities are rising again on the last trading day of the week with the Nasdaq up 2.5%. Here are your midday movers on Friday, May 27th. Dell...
Pre-Open Stock Movers:Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) 47% LOWER; reported clinical results from its C-144-01 clinical study in patients with advanced (unresectable or metastatic)...
After-Hours Stock Movers: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) 54% LOWER; reported clinical results from its C-144-01 clinical study in patients with advanced (unresectable or...
Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Basic Materials, Telecoms and Financials sectors propelled shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Telecoms, Utilities and Industrials sectors propelled shares higher while losses in the Oil & Gas,...
Investing.com – U.S. equities were lower at the close on Friday, as losses in the Financials, Healthcare and Consumer Services sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
